fda compounding glp-1 warning letters october 2025 Out of Shortage, Into Controversy: The Fight Over Compounded "semaglutide" is not FDA-approved

12:30 - GLP-1s: From Diabetes to Weight Loss 15:05 - GLP-1s vs

Adding a GLP-1 agonist, which also affects cardiac function through vagal mechanisms, creates unpredictable drug-drug interactions

Most patients experience peak side effects during the first 1 to 2 weeks after starting or increasing their dose

It works quietly behind the scenes to filter everything we encounter, from the food we eat to the air we breathe

Corrado said that few physicians are trained to care for overweight and obese patients, and she is trying to convince the Defense Health Agency to support treatment for service members either at the weight management clinic at Walter Reed or to establish similar clinics to tackle the problem across the force

In the Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved mean weight reductions of up to approximately 24% over 48 weeks